Henry Schein, Inc. (NASDAQ:HSIC) Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans raised its position in Henry Schein, Inc. (NASDAQ:HSIC) by 10.8% in the 4th quarter, Holdings Channel reports. The fund owned 116,843 shares of the company’s stock after purchasing an additional 11,428 shares during the period. Thrivent Financial for Lutherans’ holdings in Henry Schein were worth $8,085,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of HSIC. Natixis Advisors LLC grew its position in shares of Henry Schein by 18.8% during the third quarter. Natixis Advisors LLC now owns 81,877 shares of the company’s stock worth $5,969,000 after buying an additional 12,930 shares in the last quarter. Pathstone Holdings LLC grew its position in shares of Henry Schein by 3.1% during the third quarter. Pathstone Holdings LLC now owns 24,028 shares of the company’s stock worth $1,752,000 after buying an additional 732 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Henry Schein during the third quarter worth approximately $515,000. PNC Financial Services Group Inc. grew its position in shares of Henry Schein by 2.8% during the third quarter. PNC Financial Services Group Inc. now owns 86,143 shares of the company’s stock worth $6,280,000 after buying an additional 2,380 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Henry Schein by 5.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 122,721 shares of the company’s stock worth $8,946,000 after buying an additional 6,826 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Activity at Henry Schein

In related news, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now directly owns 62,688 shares in the company, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now owns 24,805 shares in the company, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

HSIC stock opened at $69.39 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a market capitalization of $8.62 billion, a price-to-earnings ratio of 28.56, a PEG ratio of 2.13 and a beta of 0.90. Henry Schein, Inc. has a 1 year low of $63.67 and a 1 year high of $82.49. The stock’s fifty day moving average is $74.82 and its two-hundred day moving average is $72.61.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.66 earnings per share. On average, research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HSIC shares. Jefferies Financial Group raised their price target on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Wells Fargo & Company began coverage on Henry Schein in a research note on Friday, February 14th. They set an “equal weight” rating and a $80.00 price objective on the stock. Mizuho began coverage on Henry Schein in a research note on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price objective on the stock. Finally, UBS Group reduced their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.